BE2011C041I2 - - Google Patents
Download PDFInfo
- Publication number
- BE2011C041I2 BE2011C041I2 BE2011C041C BE2011C041C BE2011C041I2 BE 2011C041 I2 BE2011C041 I2 BE 2011C041I2 BE 2011C041 C BE2011C041 C BE 2011C041C BE 2011C041 C BE2011C041 C BE 2011C041C BE 2011C041 I2 BE2011C041 I2 BE 2011C041I2
- Authority
- BE
- Belgium
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57992700A | 2000-05-26 | 2000-05-26 | |
| US21406500P | 2000-06-26 | 2000-06-26 | |
| PCT/US2001/017139 WO2001092337A2 (en) | 2000-05-26 | 2001-05-23 | Soluble ctla4 mutant molecules and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE2011C041I2 true BE2011C041I2 (cg-RX-API-DMAC7.html) | 2020-08-20 |
Family
ID=26908652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE2011C041C BE2011C041I2 (cg-RX-API-DMAC7.html) | 2000-05-26 | 2011-11-10 |
Country Status (41)
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6887471B1 (en) | 1991-06-27 | 2005-05-03 | Bristol-Myers Squibb Company | Method to inhibit T cell interactions with soluble B7 |
| US7094874B2 (en) | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
| US20040022787A1 (en) | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
| CA2630062C (en) * | 2000-07-03 | 2014-10-14 | Bristol-Myers Squibb Company | Methods for treating graft versus host disease and immune disorders associated with rejection using a soluble ctla4 molecule |
| ATE390931T1 (de) | 2001-05-23 | 2008-04-15 | Bristol Myers Squibb Co | Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4- mutationsmolekülen |
| CA2482042A1 (en) * | 2002-04-19 | 2003-10-30 | Bristol-Myers Squibb Company | Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid |
| DE10232697A1 (de) * | 2002-07-15 | 2004-02-05 | Universitätsklinikum Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin | Verwendung von CD152 zur Behandlung von Autoimmunkrankheiten und Entzündungen |
| EP1575998A4 (en) * | 2002-12-23 | 2007-07-25 | Bristol Myers Squibb Co | PROCESS FOR CULTIVATING MAMMALIAN CELLS FOR PROTEIN PRODUCTION |
| TWI328614B (en) * | 2002-12-23 | 2010-08-11 | Bristol Myers Squibb Co | Product quality enhancement in mammalian cell culture processes for protein production |
| WO2004060911A2 (en) | 2002-12-30 | 2004-07-22 | Amgen Inc. | Combination therapy with co-stimulatory factors |
| EP1684791A4 (en) | 2003-10-27 | 2009-07-01 | Amgen Inc | COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE REACTION TO AN IMMUNOGENIC THERAPEUTIC AGENT |
| AR058568A1 (es) | 2005-12-20 | 2008-02-13 | Bristol Myers Squibb Co | Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo |
| PT2253644E (pt) | 2005-12-20 | 2014-01-23 | Bristol Myers Squibb Co | Composições e métodos para a produção de uma composição |
| US7510844B2 (en) | 2006-01-24 | 2009-03-31 | Bristol-Myers Squibb Company | CD86 and CD80 receptor competition assays |
| WO2008005290A2 (en) | 2006-06-29 | 2008-01-10 | The Trustees Of Columbia University In The City Of New York | Methods for testing anti-thrombotic agents |
| GB0620934D0 (en) | 2006-10-20 | 2006-11-29 | Cambridge Antibody Tech | Protein variants |
| US8465741B2 (en) | 2006-12-20 | 2013-06-18 | Mmrglobal, Inc. | Antibodies and methods for making and using them |
| CA2703263C (en) | 2007-11-01 | 2014-03-18 | Perseid Therapeutics Llc | Immunosuppressive polypeptides and nucleic acids |
| AU2009298131B2 (en) * | 2008-10-02 | 2016-07-14 | Aptevo Research And Development Llc | CD86 antagonist multi-target binding proteins |
| US9540426B2 (en) | 2009-10-06 | 2017-01-10 | Bristol-Myers Squibb Company | Mammalian cell culture processes for protein production |
| WO2011113019A2 (en) * | 2010-03-12 | 2011-09-15 | Abbott Biotherapeutics Corp. | Ctla4 proteins and their uses |
| EP2678423A1 (en) | 2011-02-23 | 2014-01-01 | Amgen Inc. | Cell culture media for uvc exposure and methods related thereto |
| WO2013010537A1 (en) | 2011-07-20 | 2013-01-24 | Aarhus Universitet | Method of treating morphea |
| US9758566B2 (en) | 2012-03-29 | 2017-09-12 | The General Hospital Corporation | Recombinant cytotoxic T-lymphocyte-associated protein 4 (CTLA4) |
| MX355234B (es) * | 2012-05-11 | 2018-04-11 | Medimmune Ltd | Variantes de antigeno 4 del linfocito t citotoxico (ctla-4). |
| US8735359B2 (en) | 2012-05-24 | 2014-05-27 | Orban Biotech Llc | Combinations of modalities for the treatment of diabetes |
| AU2013284460A1 (en) * | 2012-06-27 | 2015-01-29 | Dmnomore | CTLA4 fusion proteins for the treatment of diabetes |
| US20140112958A1 (en) | 2012-10-24 | 2014-04-24 | Mwm Biomodels Gmbh | Pancreatic islets of transgenic LEA29Y animals for treating diabetes |
| CN104740608A (zh) * | 2013-12-30 | 2015-07-01 | 上海中信国健药业股份有限公司 | 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途 |
| MX376230B (es) | 2014-01-13 | 2025-03-07 | Amgen Inc | Regulación del metábolismo de ornitina para manipular el contenido de glicoformas ricas en manosa de proteínas recombinantes. |
| GB2523399B (en) | 2014-02-25 | 2019-03-13 | Orban Tihamer | A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence |
| KR102391259B1 (ko) | 2014-06-04 | 2022-04-26 | 암젠 인크 | 포유류 세포 배양물을 회수하는 방법 |
| CA2969225C (en) | 2014-12-01 | 2023-08-22 | Amgen Inc. | Process for manipulating the level of glycan content of a glycoprotein |
| WO2016130734A1 (en) | 2015-02-11 | 2016-08-18 | Bristol-Myers Squibb Company | Use of phenolic antioxidants in cell culture for the production of proteins |
| SMT202100467T1 (it) | 2015-04-17 | 2021-09-14 | Alpine Immune Sciences Inc | Proteine immunomodulatorie con affinità regolabili |
| EP3347486A4 (en) | 2015-09-09 | 2019-06-19 | The Trustees of Columbia University in the City of New York | REDUCTION OF ER-MAM-LOCALIZED APP-C99 AND METHOD FOR THE TREATMENT OF ALZHEIMER DISEASE |
| KR20180073693A (ko) | 2015-11-09 | 2018-07-02 | 브리스톨-마이어스 스큅 컴퍼니 | Cho 세포에서 생산되는 폴리펩티드의 품질 속성을 조작하는 방법 |
| AU2017248830B2 (en) | 2016-04-15 | 2023-03-09 | Alpine Immune Sciences, Inc. | CD80 variant immunomodulatory proteins and uses thereof |
| EP3491013A1 (en) | 2016-07-28 | 2019-06-05 | Alpine Immune Sciences, Inc. | Cd155 variant immunomodulatory proteins and uses thereof |
| EP3515489B1 (en) * | 2016-09-19 | 2025-11-05 | OncoC4, Inc. | Cd80 and cd86 binding protein compositions and uses thereof |
| CN107987153A (zh) * | 2016-10-27 | 2018-05-04 | 广东香雪精准医疗技术有限公司 | 高亲和力的可溶性pd-1分子 |
| CN116732106A (zh) | 2017-04-20 | 2023-09-12 | E开创生物技术股份有限公司 | 产生基因修改的动物的方法 |
| EP3694870A1 (en) * | 2017-10-10 | 2020-08-19 | Alpine Immune Sciences, Inc. | Ctla-4 variant immunomodulatory proteins and uses thereof |
| SG11202006148UA (en) | 2018-01-03 | 2020-07-29 | Alpine Immune Sciences Inc | Multi-domain immunomodulatory proteins and methods of use thereof |
| CN115227824A (zh) * | 2018-11-12 | 2022-10-25 | 中南大学湘雅二医院 | 免疫检查点的抑制剂在制备治疗青光眼和其他眼部免疫损伤机制相关疾病药物中的应用 |
| CN113727998A (zh) | 2018-11-30 | 2021-11-30 | 高山免疫科学股份有限公司 | Cd86变体免疫调节蛋白及其用途 |
| MX2022002337A (es) | 2019-08-27 | 2022-06-08 | Tonix Pharma Ltd | Polipéptidos de tff2 modificados. |
| IL309560B2 (en) | 2019-12-06 | 2025-05-01 | Regeneron Pharma | Anti-VEGF protein preparations and methods for their production |
| MX2022013812A (es) | 2020-05-08 | 2022-12-15 | Regeneron Pharma | Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer. |
| US12202882B2 (en) | 2020-05-08 | 2025-01-21 | Alpine Immune Sciences, Inc. | APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof |
| EP4168807A1 (en) | 2020-06-18 | 2023-04-26 | Regeneron Pharmaceuticals, Inc. | Heavy peptide approach to accurately measure unprocessed c-terminal lysine |
| CN116601279A (zh) | 2020-07-28 | 2023-08-15 | 思进股份有限公司 | 用于生产多肽的方法和系统 |
| IL302830A (en) | 2020-11-13 | 2023-07-01 | Egenesis Inc | Cells, tissues, organs and animals with one or more genes that have been modified for improved survival and tolerance of a different-sex transplant |
| US20250040546A1 (en) | 2021-12-16 | 2025-02-06 | Bristol-Myers Squibb Company | Detergent for viral inactivation |
| EP4486778A1 (en) | 2022-03-02 | 2025-01-08 | Regeneron Pharmaceuticals, Inc. | Manufacturing process for high titer antibody |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5844095A (en) | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
| US5851795A (en) * | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| DE69226871T3 (de) * | 1991-06-27 | 2009-09-24 | Bristol-Myers Squibb Co. | CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung |
| ZA98533B (en) * | 1997-01-31 | 1999-07-22 | Bristol Myers Squibb Co | Soluble CTLA4 mutant molecules and uses thereof. |
| JP3521382B2 (ja) * | 1997-02-27 | 2004-04-19 | 日本たばこ産業株式会社 | 細胞間接着及びシグナル伝達を媒介する細胞表面分子 |
| GB9809280D0 (en) * | 1998-04-30 | 1998-07-01 | Rpms Technology Ltd | Immunosupression |
| AU1102000A (en) * | 1998-10-07 | 2000-04-26 | Millennium Pharmaceuticals, Inc. | Novel th2-specific molecules and uses thereof |
| CA2630062C (en) * | 2000-07-03 | 2014-10-14 | Bristol-Myers Squibb Company | Methods for treating graft versus host disease and immune disorders associated with rejection using a soluble ctla4 molecule |
-
2001
- 2001-05-23 TW TW090112431A patent/TWI314933B/zh not_active IP Right Cessation
- 2001-05-23 DE DE60104282T patent/DE60104282T2/de not_active Expired - Lifetime
- 2001-05-23 CN CNB018101453A patent/CN1309735C/zh not_active Expired - Lifetime
- 2001-05-23 AU AU2001263466A patent/AU2001263466C1/en not_active Expired
- 2001-05-23 EP EP01937764A patent/EP1248802B9/en not_active Expired - Lifetime
- 2001-05-23 IL IL152315A patent/IL152315A/en active Protection Beyond IP Right Term
- 2001-05-23 HK HK03100239.8A patent/HK1048126B/en not_active IP Right Cessation
- 2001-05-23 EP EP15197082.9A patent/EP3029062A1/en not_active Withdrawn
- 2001-05-23 KR KR1020027015946A patent/KR100895134B1/ko not_active Expired - Lifetime
- 2001-05-23 MY MYPI20012427A patent/MY136113A/en unknown
- 2001-05-23 GE GE4987A patent/GEP20053658B/en unknown
- 2001-05-23 TR TR2004/02703T patent/TR200402703T4/xx unknown
- 2001-05-23 EP EP04008908.8A patent/EP1536234B1/en not_active Expired - Lifetime
- 2001-05-23 EG EG20010548A patent/EG24459A/xx active
- 2001-05-23 DK DK01937764T patent/DK1248802T3/da active
- 2001-05-23 AU AU6346601A patent/AU6346601A/xx active Pending
- 2001-05-23 HU HU0302201A patent/HU228137B1/hu active Protection Beyond IP Right Term
- 2001-05-23 WO PCT/US2001/017139 patent/WO2001092337A2/en not_active Ceased
- 2001-05-23 CN CNA2007100840790A patent/CN101255192A/zh active Pending
- 2001-05-23 BR BRPI0111191 patent/BRPI0111191B8/pt not_active IP Right Cessation
- 2001-05-23 UA UA20021210563A patent/UA87432C2/uk unknown
- 2001-05-23 PL PL366231A patent/PL206267B1/pl unknown
- 2001-05-23 SK SK1570-2002A patent/SK288131B6/sk not_active IP Right Cessation
- 2001-05-23 RU RU2002131588/13A patent/RU2283847C2/ru active Protection Beyond IP Right Term
- 2001-05-23 AT AT01937764T patent/ATE271066T1/de active
- 2001-05-23 CZ CZ2002-3892A patent/CZ304451B6/cs not_active IP Right Cessation
- 2001-05-23 UY UY26723A patent/UY26723A1/es not_active IP Right Cessation
- 2001-05-23 SI SI200130186T patent/SI1248802T1/xx unknown
- 2001-05-23 TW TW097137809A patent/TWI319405B/zh not_active IP Right Cessation
- 2001-05-23 PT PT01937764T patent/PT1248802E/pt unknown
- 2001-05-23 EE EEP201100050A patent/EE05557B1/xx unknown
- 2001-05-23 CA CA002409748A patent/CA2409748C/en not_active Expired - Lifetime
- 2001-05-23 KR KR1020077017691A patent/KR100889887B1/ko not_active Expired - Lifetime
- 2001-05-23 JP JP2002500948A patent/JP4328525B2/ja not_active Expired - Lifetime
- 2001-05-23 ES ES04008908T patent/ES2571852T3/es not_active Expired - Lifetime
- 2001-05-23 MX MXPA02011534A patent/MXPA02011534A/es active IP Right Grant
- 2001-05-23 ES ES01937764T patent/ES2225549T3/es not_active Expired - Lifetime
- 2001-05-23 AR ARP010102449A patent/AR031699A1/es active IP Right Grant
- 2001-05-23 EE EEP200200659A patent/EE05458B1/xx active Protection Beyond IP Right Term
- 2001-05-23 PE PE2001000465A patent/PE20011338A1/es active IP Right Grant
-
2002
- 2002-11-04 ZA ZA200208944A patent/ZA200208944B/en unknown
- 2002-11-13 LT LT2002114A patent/LT5133B/lt not_active IP Right Cessation
- 2002-11-25 NO NO20025656A patent/NO330797B1/no not_active IP Right Cessation
- 2002-11-26 EC EC2002004365A patent/ECSP024365A/es unknown
- 2002-12-19 LV LVP-02-214A patent/LV12994B/en unknown
-
2011
- 2011-11-10 BE BE2011C041C patent/BE2011C041I2/fr unknown
- 2011-11-16 LU LU91902C patent/LU91902I2/fr unknown
- 2011-12-05 DE DE201112100063 patent/DE122011100063I1/de active Pending
- 2011-12-07 FR FR11C0053C patent/FR11C0053I2/fr active Active
- 2011-12-12 CY CY2011019C patent/CY2011019I2/el unknown
- 2011-12-15 NO NO2011027C patent/NO2011027I1/no not_active IP Right Cessation
-
2013
- 2013-04-12 HU HUS1300012C patent/HUS1300012I1/hu unknown
-
2016
- 2016-06-10 CY CY20161100511T patent/CY1117625T1/el unknown